ZyVersa Therapeutics furnishes Q3 2025 unaudited results in 8-K

Rhea-AI Filing Summary

ZyVersa Therapeutics, Inc. (ZVSA) filed a current report to announce that it released a press release with its unaudited financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is being furnished rather than filed, which means it is not automatically subject to certain liability provisions under the securities laws or incorporated into other securities filings unless specifically referenced. The company’s common stock, par value $0.0001 per share, trades under the symbol ZVSA and is quoted on the OTCQB Venture Market.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001859007 0001859007 2025-11-19 2025-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2025

ZYVERSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41184		86-2685744
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2200 N. Commerce Parkway, Suite 208, Weston, Florida		33326
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (754) 231-1688

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ZVSA		*

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

* The company’s common stock is quoted on the OTCQB® Venture Market under the symbol “ZVSA.”

Item 2.02 Results of Operations and Financial Condition

On November 19, 2025, ZyVersa Therapeutics, Inc. (the “Company”) issued a press release announcing its unaudited financial results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information furnished under Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated November 19, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 19, 2025	ZYVERSA THERAPEUTICS, INC.
	/s/ Stephen Glover
	Stephen Glover
	Chief Executive Officer

FAQ

What did ZyVersa Therapeutics (ZVSA) announce in this 8-K filing?

ZyVersa Therapeutics announced that it issued a press release reporting its unaudited financial results for the quarter ended September 30, 2025, which is furnished as Exhibit 99.1.

Which period do the latest ZyVersa Therapeutics (ZVSA) financial results cover?

The unaudited financial results announced by ZyVersa Therapeutics cover the quarter ended September 30, 2025.

How is the ZyVersa Therapeutics (ZVSA) press release treated under securities laws?

The press release, furnished under Item 2.02 along with Exhibit 99.1, is deemed furnished and not filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated into other filings unless specifically referenced.

Where is ZyVersa Therapeutics (ZVSA) common stock traded?

ZyVersa Therapeutics’ common stock is quoted on the OTCQB Venture Market under the symbol ZVSA.

Who signed the ZyVersa Therapeutics (ZVSA) 8-K reporting the quarterly results press release?

The 8-K was signed on behalf of ZyVersa Therapeutics, Inc. by Stephen Glover, its Chief Executive Officer.

What exhibits are included with this ZyVersa Therapeutics (ZVSA) 8-K?

The 8-K includes Exhibit 99.1, a press release dated November 19, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.